Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of ...

Clinical-stage biotech company aTyr Pharma (ATYR) has seen a significant 24% increase in stock value over the past week, as the company posted ...

Q4 2024 Earnings Call Transcript March 13, 2025 aTyr Pharma, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. Operator: Good afternoon, ladies and gentlemen, and ...

With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...

Tyr Pharma Inc (ATYR) reports robust financial health and significant progress in its pivotal phase three study for pulmonary ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.

SAN DIEGO - aTyr Pharma, Inc. (NASDAQ: ATYR) reported a narrower-than-expected fourth quarter loss on Wednesday, but shares fell 4.8% in after-hours trading as investors focused on the company’s cash ...

Peer-reviewed publication validates efzofitimod's unique anti-inflammatory mechanism of action on macrophages through ...

SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl ...

Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology. It affects the lungs in over 90% of patients yet extra-pulmonary and multi-organ involvement is common. Spontaneous ...